Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jiangniaosuan formula
- Development stage
- Phase 4
- Lead developer
- Shanghai Pudong Hospital
- Administration
- Oral
01
Overview
Jiangniaosuan formula is a traditional Chinese herbal medicine developed by Shanghai Pudong Hospital for the treatment of hyperuricemia and gout. It is typically used as an adjunctive therapy alongside standard xanthine oxidase inhibitors like febuxostat. The formula is designed to reduce and stabilize serum uric acid levels while potentially addressing comorbid conditions such as dyslipidemia and insulin resistance. In clinical studies, it has been evaluated for its ability to improve traditional Chinese medicine (TCM) syndrome scores and maintain therapeutic effects after the cessation of treatment.
- Other names
- JiangniaosuanJiangniaosuan decoction
02
Targets
BCL-2 (BCL-2 family)CASP3 (Caspase-3)EZH2 (Histone-lysine N-methyltransferase EZH2)HIF1A (Hypoxia-inducible factor 1-alpha)
Beyond the preview
Go deeper on Jiangniaosuan formula.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jiangniaosuan formula.